581
Participants
Start Date
August 31, 2007
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
Alemtuzumab
Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
Interferon beta-1a
Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Royal Melbourne Hospital, Department of Neurology, Ward 4 East, Parkville
St Vincent's Hospital, Fitzroy
Austin Health, Heidelberg
The Wesley Research Institute, Auchenflower
Royal Hobart Hospital, Hobart
North Central Neurology Associates, P.C., Cullman
Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix
Mayo Clinic Arizona, Scottsdale
Northwest NeuroSpecialists, PLLC, Tucson
Advanced Neurosciences Research, Fort Collins
Neurological Associates, Pompano Beach
Axiom Clinical Research of Florida, Tampa
Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls
Consultants in Neurology, Ltd., Northbrook
Fort Wayne Neurological Center, Fort Wayne
University of Kansas Medical Center, Kansas City
MidAmerican Neuroscience Institute, Lenexa
Associates in Neurology, PSC, Lexington
University of Louisville Research Foundation, Louisville
Louisiana State University Health Sciences Center, Shreveport
UMass Memorial Medical Center, Worcester
University of Michigan Health System, Ann Arbor
Wayne State University, Detroit
University of Nevada School of Medicine, Las Vegas
Dartmouth-Hitchcock Medical Center, Lebanon
University of New Mexico, Health Sciences Center, MS Specialty Clinic, Albuquerque
Empire Neurology, Latham
Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue
University of Rochester Medical Center, Rochester
Carolinas Medical Center (CMC), Neurosciences & Spine Institute (NSSI), Charlotte
The Ohio State University Medical Center, Multiple Sclerosis Center, Columbus
Oak Clinic for Multiple Sclerosis, Uniontown
MS Center of Oklahoma, Oklahoma City
Lehigh Valley Hospital Neurosciences and Pain Research, Allentown
Advanced Neurosciences Institute, Franklin
Biomedical Research Alliance of NY, LLC, Franklin
Hope Neurology PC, Knoxville
Baylor College of Medicine, Maxine Mesinger MS Clinic, Houston
Central Texas Neurology, Round Rock
Integra Clinical Research, San Antonio
Neurology Center of San Antonio, San Antonio
DIABAID, Buenos Aires
Griffith University School of Medicine, Southport
The Queen Elizabeth Hospital, Woodville South
Concord Repatriation General Hospital, Concord
Westmead Hospital, Westmead
Hospital da Restauracao, Av Governador Agamenon Magalhaes, Recife
Hospital Sao Lucas PUC-RS, Porto Alegre
Hospital de Clínicas USP, São Paulo
University of Calgary and Foothills Medical Cenre, Calgary
UBC Hospital, Vancouver
The Ottawa Hospital, General Campus, Ottawa
Clinique Nuero-outaouais, Gatineau
Clinique Neuro rive-sud, Recherche Sepmus, Inc., Greenfield Park
Clinical Hospital Centre Rijeka, Rijeka
General Hospital Varazdin, Varaždin
"Clinical Hospital Centre Sestre Milosrdnice", Zagreb
Clinical Hospital Centre Zagreb, Zagreb
"General Hospital Sveti Duh", Zagreb
Department of Neurology, 1st Faculty of Medicine and General Teaching Hospital, Prague
Krajska zdravotni a.s., Hospital Teplice, Teplice
Hopital Purpan, Toulouse
Judisches Krankenhaus Berlin, Berlin
Universitätsklinik Carl Gustav Carus Dresden, Dresden
Klinikum der Goethe Universität Frankfurt, Frankfurt
Medizinische Hochschule Hannover, Hanover
Oberhavelkliniken Hennigsdorf, Hennigsdorf
Asklepios Klinikum Brandenburg, Teupitz
Hospital Angeles del Pedregal, Camino de Santa Teresa, Mexico City
Hospital Medica Sur CIF-BIOTEC, Mexico City
Clinical Neurology Centre Sp. z o.o. (Ltd), Krakow
Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz
Independent Public Teaching Hospital No. 4 in Lublin, Lublin
Heliodor Swiecicki Teaching Hospital of the Poznan University of Medical Sciences, Poznan
"Research Medical Complex Your Health Ltd", Kazan'
Moscow City Hospital #11, Moscow
Moscow State Medical Institution City Clinical Hospital #11, Moscow
Scientific Neurology Center RAMS, Moscow
Municipal City Hospital #33, Nizhny Novgorod
Federal State Institution Siberian Rettitorial Medical Center under Federal Medical-Biological Agency of Russia, Novosibirsk
City Clinical Hospital #2, Pyatigorsk
Institute of Human Brain RAS, Saint Petersburg
Nikolaevskaya Hospital, Saint Petersburg
St. Petersburg Pavlov State Medical University, Saint Petersburg
Samara Regional Clinical Hospital n.a. Kalinin, Samara
State Medical Institution: Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa
Clinical Centre Serbia, Institute for Neurology, Belgrade
Military Medical Academy, Belgrade
Clinical centre Kragujevac, Kragujevac
Clinical Center Nis, Clinic for neurology, Niš
Clinical Centre of Vojvodina, Clinic for neurology, Novi Sad
Sahlgrenska University Hospital, Gothenburg
Chernihiv Regional Hospital, Chernihiv
Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Department of Neuroinfection and Multiple Sclerosis, Kharkiv
Hospoital of the Directorate of the Medical Corps within the Ukrainian Security Service, Neurology Department, Kyiv
Kyiv Municipal Clinical Hospital #4, Kyiv
Danylo Halytsky Lviv National Medical University, Lviv
Department Of Neurosciences, Addenbrookes Hospital, Cambridge
Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London
University Hospital of Wales, Cardiff
Royal Hallamshire Hospital, Sheffield
Collaborators (1)
Bayer
INDUSTRY
Genzyme, a Sanofi Company
INDUSTRY